| ACG | American College of Gastroenterology |
| AEs | adverse events |
| CAP | community-acquired pneumonia |
| CI | confidence interval |
| DGER | duodeno-gastro-esophageal reflux |
| ECL | Enterochromaffin-like |
| EE | erosive esophagitis |
| FDA | Food and Drug Administration |
| FSSG | Frequency Scale for Symptoms of Gastroesophageal Reflux Disease |
| GERD | gastroesophageal reflux disease |
| H+/K+-ATPase | hydrogen–potassium ATPase |
| H2RAs | H2 receptor antagonists |
| HRM | high-resolution manometry |
| HRT | Holding Time Radio |
| JADER | Japanese Adverse Drug Event Report |
| LA | Los Angeles |
| LES | lower esophageal sphincter |
| MAD | multiple ascending dose |
| NERD | non-erosive reflux disease |
| NETs | neuroendocrine tumors |
| PCABs | potassium-competitive acid blockers |
| PPIs | proton pump inhibitors |
| PSQI | Pittsburgh Sleep Quality Index |
| RCT | randomized controlled trial |
| RE | reflux esophagitis |
| SAD | single ascending dose |
| SAEs | serious adverse events |
| SUCRA | Surface Under the Cumulative Ranking Curve |